NCT04444804View on ClinicalTrials.gov

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

CompletedOBSERVATIONAL
Enrollment

22,153

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Venous Thromboembolism
Interventions
DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Dosage at the discretion of the treating physician

DRUG

LMWH and Phenprocoumon

Dosage at the discretion of the treating physician

Trial Locations (1)

Unknown

Multiple facilities, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY